Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
4934150
Reference Type
Journal Article
Title
Double-blind trial of a new topical corticosteroid in a US naval hospital
Author(s)
Levy, J; Highly, FM, Jr
Year
1974
Is Peer Reviewed?
1
Journal
Military Medicine
ISSN:
0026-4075
EISSN:
1930-613X
Volume
139
Issue
9
Page Numbers
728–730
Language
English
DOI
10.1093/milmed/139.9.728
Web of Science Id
WOS:A1974U019300013
Abstract
IPA COPYRIGHT: ASHP Fluocinonide, formulated at a concentration of 0.05% in FAPG base, (stearyl alcohol, glycerine, polyethylene glycol, and propylene glycol) was evaluated in a double-blind study conducted on 56 patients with symmetrical, steroid-responsive lesions. There were 25 cases of psoriasis, 22 of atopic dermatitis, and 9 miscellaneous cases. Patients were given 2 tubes of medication at each visit, one labeled right side, the other labeled left side. The cream was applied twice daily. After the initial evaluation, patients were seen at intervals of approximately 7, 14, and 21 days. Results in all dermatoses were quite good with fluocinonide when compared with placebo. A number of patients complained of minor side effects such as burning, itching, dryness, and scaling. One patient dropped out because the lesions appeared worsened after the 1 week. Results appear to confirm the clinical efficacy of the formulation in the treatment of corticosteroid responsive dermatoses.
Tags
OPPT
•
Fatty Alcohols
Literature Search
Human Health
Toxline (private)
Environmental Hazard
Toxline (private)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity